* Fusion Pharmaceuticals Inc FUSN.OQ reported a quarterly
adjusted loss of 39 cents per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of -55 cents. The mean expectation of
twelve analysts for the quarter was for a loss of 34 cents per
share. Wall Street expected results to range from -42 cents
to -27 cents per share.
* Reported revenue was zero; analysts expected $409.90
thousand.
* Fusion Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 39 cents.
* The company reported a quarterly loss of $28.18 million.
* Fusion Pharmaceuticals Inc shares had risen by 120.4% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 1.9%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 9
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is "hold."
Wall Street's median 12-month price target for Fusion
Pharmaceuticals Inc is $21.00
This summary was machine generated from LSEG data March 20 at
08:50 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.34 -0.39 Missed
Sep. 30 2023 -0.40 -0.25 Beat
Jun. 30 2023 -0.39 -0.38 Beat
Mar. 31 2023 -0.32 -0.45 Missed